Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,695 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 17, 2026, 4:45 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

NCT06958211
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
67
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

NCT02570854
View directory record Official record
Conditions
Anemia, Iron-Deficiency
Interventions
CSJ137, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 17, 2026, 4:45 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

NCT03573401
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma
Interventions
Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Fountain Valley, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

NCT05579730
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035%, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Phoenix, Arizona • Andover, Massachusetts • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

NP2 Enkephalin For Treatment of Intractable Cancer Pain

NCT01291901
View directory record Official record
Conditions
Intractable Pain, Neoplasms
Interventions
NP2, Placebo
Biological
Lead sponsor
Diamyd Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
18
States / cities
Phoenix, Arizona • Tucson, Arizona • Corona, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 17, 2026, 4:45 AM EDT
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
View directory record Official record
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis

NCT01799824
View directory record Official record
Conditions
Primary Axillary Hyperhidrosis
Interventions
ANT-1403, placebo
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 4:45 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

NCT05608343
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Difamilast, Placebo
Drug
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
2 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 17, 2026, 4:45 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019

NCT04511650
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome (ARDS)
Interventions
Razuprotafib Subcutaneous Solution, Placebo Subcutaneous Solution
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI

NCT02723539
View directory record Official record
Conditions
Diabetic Foot Infection
Interventions
MBN-101, Placebo
Drug
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Fresno, California • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

NCT05432596
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With Presbyopia

NCT03857542
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine HCl Ophthalmic Solution, Vehicle
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Dothan, Alabama • Prescott, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

NCT02324270
View directory record Official record
Conditions
Ankle Sprain
Interventions
Diclofenac epolamine, Placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
658 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
31
States / cities
Birmingham, Alabama • Goodyear, Arizona • Carlsbad, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 17, 2026, 4:45 AM EDT
Recruiting Phase 2 Interventional

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06686472
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 17, 2026, 4:45 AM EDT
Not listed Not applicable Interventional

Using the Connect: Game Based Intervention

NCT05927194
View directory record Official record
Conditions
Adolescent Behavior, Contraception, Health Behavior
Interventions
Using the Connect
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
9 Years to 15 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 1 Interventional

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury

NCT02248051
View directory record Official record
Conditions
Acute Kidney Injury (Nontraumatic)
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Anaheim, California • Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 17, 2026, 4:45 AM EDT
Not listed Phase 2 Interventional

A Study of TL-925 for the Treatment of Allergic Conjunctivitis

NCT06153342
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 17, 2026, 4:45 AM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 17, 2026, 4:45 AM EDT